Valneva Se ADR (VALN) Stock Price, Quote & News - Mboum

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 2 28 07 37 10

Fax: 33 2 28 07 37 11

Website: valneva.com

Address:

6 rue Alain Bombard, Saint-Herblain, France

SuperGreenToday Apr. 1 at 12:16 AM

0 · Reply

PickelballPaul Mar. 31 at 11:50 AM

$VALN Covered by CNN today … segment on Pfizer and Valneva … both named … and Lyme Vax data and history of prior vax withdrawn from market

0 · Reply

ajmore Mar. 31 at 11:46 AM

$VALN $APLS and $CNTA acquired! pharma heating up.

0 · Reply

ajmore Mar. 27 at 4:59 PM

$VALN attending vaccine conf next week!

0 · Reply

ajmore Mar. 24 at 7:09 AM

$VALN Stifel keeps buys and target 8.5! My take on the data; its strong data and fda will approve. dont forget that this will be release 1.0 of the vaccine and 2.0 will come and then 3.0... thats how regulators see it.

0 · Reply

Skywulf Mar. 24 at 1:10 AM

$VALN wow a 40% drop - basically everyone banked on that lyme vaccine and now with the less favorable conditions and chance on approval, you can see everyone pulled out

0 · Reply

Andadiser Mar. 23 at 8:04 PM

0 · Reply

Dr_Jan_Itor Mar. 23 at 5:59 PM

$VALN My shoe has a better puls than this POS. No rebound at all

0 · Reply

ajmore Mar. 23 at 4:54 PM

$VALN Some takeaways: Reading through comments today; 1. was it a miss when a seondary planning (by measuring from day 1 after the shot) did meet primary and seocndary endpoints! No it wasnt a miss. 2. Lyme disease vaccine is actually one of the few pushed by Kennedy! 3. 470000 infections a year in US alone. If burden is reduced by 280000 (70% reduction) then the benefit is massive. 3. The talk is about a potential early meetings because of the interest on the two regulatory sides. 4. Pfizer would make a move and acquire valneva. a 100%-150% premium and its theirs!.

1 · Reply

prismmarketview Mar. 23 at 3:30 PM

$PFE $VALN pushing forward on Lyme disease vaccine despite missing Phase 3 primary endpoint. The case: 70%+ efficacy. No safety concerns. Zero approved competition since 2002. 476K U.S. cases/year. FDA submission planned for 2026. Peak sales est. $1B+. The risk: regulators may not look past the trial miss. Under the current FDA climate, this one's a real wildcard. 🎯 Not financial advice. Regulatory outcome pending. https://prismmarketview.com/pfizer-is-pushing-forward-on-a-lyme-disease-vaccine-even-after-missing-its-trial-goal/

0 · Reply

Latest News on VALN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

Tue, 31 Mar 2026 18:06:00 -0400 - 17 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

Thu, 26 Mar 2026 12:45:00 -0400 - 5 days ago

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

Thu, 26 Mar 2026 10:00:00 -0400 - 6 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN

Tue, 24 Mar 2026 17:49:00 -0400 - 7 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN

Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges

2026-03-23T20:51:10.000Z - 8 days ago

Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Mon, 23 Mar 2026 12:46:00 -0400 - 8 days ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Lyme disease vaccine 70 percent effective: Pfizer

2026-03-23T16:29:29.000Z - 8 days ago

Lyme disease vaccine 70 percent effective: Pfizer

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial

2026-03-23T15:19:35.000Z - 9 days ago

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Mon, 23 Mar 2026 10:35:19 -0400 - 9 days ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

2026-03-23T14:35:19.000Z - 9 days ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mon, 23 Mar 2026 09:36:42 -0400 - 9 days ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Valneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 Trial; Shows More Than 70% Efficacy

2026-03-23T13:22:10.000Z - 9 days ago

Valneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 Trial; Shows More Than 70% Efficacy

Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session

2026-03-23T12:03:10.000Z - 9 days ago

Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Pfizer: Lyme Disease Vaccine Candidate Shows Strong Efficacy In Phase 3 VALOR Trial

2026-03-23T11:46:13.000Z - 9 days ago

Pfizer: Lyme Disease Vaccine Candidate Shows Strong Efficacy In Phase 3 VALOR Trial

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mon, 23 Mar 2026 07:07:00 -0400 - 9 days ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mon, 23 Mar 2026 07:02:00 -0400 - 9 days ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mon, 23 Mar 2026 06:47:13 -0400 - 9 days ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mon, 23 Mar 2026 06:45:00 -0400 - 9 days ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

2026-03-18T21:00:27.000Z - 13 days ago

Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

Full Year 2025 Valneva SE Earnings Call Transcript

2026-03-18T19:00:18.000Z - 13 days ago

Full Year 2025 Valneva SE Earnings Call Transcript

Valneva (VALN) Partners with Elaris FlexCo for Vaccine Technology

2026-03-18T13:33:19.000Z - 14 days ago

Valneva (VALN) Partners with Elaris FlexCo for Vaccine Technology

Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

2026-03-18T12:02:07.000Z - 14 days ago

Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

Mar 18, 2026, 8:00 AM EDT - 14 days ago

Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

Earnings Scheduled For March 18, 2026

2026-03-18T11:11:10.000Z - 14 days ago

Earnings Scheduled For March 18, 2026

Valneva Reports Audited FY25 Results Ahead Of Full Presentation Later Today

2026-03-18T08:36:06.000Z - 14 days ago

Valneva Reports Audited FY25 Results Ahead Of Full Presentation Later Today

Valneva (VALN) Reports 3% Revenue Growth, Projects Lower 2026 Sales

2026-03-18T07:56:51.000Z - 14 days ago

Valneva (VALN) Reports 3% Revenue Growth, Projects Lower 2026 Sales

Valneva FY25 Net Loss Widens, Product Sales Down; Sees Lower Revenues In FY26

2026-03-18T07:50:09.000Z - 14 days ago

Valneva FY25 Net Loss Widens, Product Sales Down; Sees Lower Revenues In FY26

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Mar 18, 2026, 2:00 AM EDT - 14 days ago

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026

Mar 9, 2026, 12:45 PM EDT - 22 days ago

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026

VALNEVA Declaration of shares and voting rights: February 28, 2026

Mar 6, 2026, 12:00 PM EST - 25 days ago

VALNEVA Declaration of shares and voting rights: February 28, 2026

Valneva to Participate in Upcoming Investor Conferences

Mar 2, 2026, 11:45 AM EST - 4 weeks ago

Valneva to Participate in Upcoming Investor Conferences

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook

Feb 19, 2026, 1:00 AM EST - 5 weeks ago

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook

Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom

Feb 13, 2026, 11:45 AM EST - 6 weeks ago

Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom

VALNEVA Declaration of shares and voting rights: January 31, 2026

Feb 6, 2026, 2:30 AM EST - 7 weeks ago

VALNEVA Declaration of shares and voting rights: January 31, 2026

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®

Feb 3, 2026, 1:00 AM EST - 2 months ago

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva withdraws application for standard US approval of its chikungunya shot

Jan 19, 2026, 2:00 PM EST - 2 months ago

Valneva withdraws application for standard US approval of its chikungunya shot

Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

Jan 19, 2026, 12:00 PM EST - 2 months ago

Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Jan 9, 2026, 1:00 AM EST - 2 months ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Valneva SE - Declaration of voting rights - December 2025

Jan 8, 2026, 12:30 PM EST - 2 months ago

Valneva SE - Declaration of voting rights - December 2025

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

Dec 31, 2025, 11:45 AM EST - 3 months ago

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

Dec 10, 2025, 11:45 AM EST - 3 months ago

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

VALNEVA Declaration of shares and voting rights: November 30, 2025

Dec 5, 2025, 12:34 PM EST - 4 months ago

VALNEVA Declaration of shares and voting rights: November 30, 2025

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Nov 26, 2025, 12:30 PM EST - 4 months ago

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva to Further Consolidate its Operations in France

Nov 26, 2025, 11:30 AM EST - 4 months ago

Valneva to Further Consolidate its Operations in France

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Nov 26, 2025, 6:37 AM EST - 4 months ago

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Nov 26, 2025, 1:00 AM EST - 4 months ago

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Nov 20, 2025, 1:00 AM EST - 4 months ago

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Nov 4, 2025, 1:00 AM EST - 5 months ago

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Oct 27, 2025, 12:45 PM EDT - 5 months ago

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Oct 6, 2025, 11:35 AM EDT - 6 months ago

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Sep 30, 2025, 1:00 AM EDT - 6 months ago

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Sep 3, 2025, 1:00 AM EDT - 7 months ago

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

Aug 25, 2025, 12:02 PM EDT - 7 months ago

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

Johnson Fistel Investigates Valneva Following FDA Suspension

Aug 25, 2025, 10:43 AM EDT - 7 months ago

Johnson Fistel Investigates Valneva Following FDA Suspension

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Aug 25, 2025, 10:29 AM EDT - 7 months ago

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Aug 25, 2025, 1:16 AM EDT - 7 months ago

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Aug 25, 2025, 1:00 AM EDT - 7 months ago

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Aug 18, 2025, 1:00 AM EDT - 8 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 1:00 AM EDT - 8 months ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Aug 7, 2025, 1:18 AM EDT - 8 months ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Jul 29, 2025, 10:00 AM EDT - 8 months ago

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Jul 11, 2025, 11:35 AM EDT - 9 months ago

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Jul 11, 2025, 8:18 AM EDT - 9 months ago

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Jun 26, 2025, 1:00 AM EDT - 9 months ago

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

SuperGreenToday Apr. 1 at 12:16 AM

0 · Reply

PickelballPaul Mar. 31 at 11:50 AM

$VALN Covered by CNN today … segment on Pfizer and Valneva … both named … and Lyme Vax data and history of prior vax withdrawn from market

0 · Reply

ajmore Mar. 31 at 11:46 AM

$VALN $APLS and $CNTA acquired! pharma heating up.

0 · Reply

ajmore Mar. 27 at 4:59 PM

$VALN attending vaccine conf next week!

0 · Reply

ajmore Mar. 24 at 7:09 AM

$VALN Stifel keeps buys and target 8.5! My take on the data; its strong data and fda will approve. dont forget that this will be release 1.0 of the vaccine and 2.0 will come and then 3.0... thats how regulators see it.

0 · Reply

Skywulf Mar. 24 at 1:10 AM

$VALN wow a 40% drop - basically everyone banked on that lyme vaccine and now with the less favorable conditions and chance on approval, you can see everyone pulled out

0 · Reply

Andadiser Mar. 23 at 8:04 PM

0 · Reply

Dr_Jan_Itor Mar. 23 at 5:59 PM

$VALN My shoe has a better puls than this POS. No rebound at all

0 · Reply

ajmore Mar. 23 at 4:54 PM

$VALN Some takeaways: Reading through comments today; 1. was it a miss when a seondary planning (by measuring from day 1 after the shot) did meet primary and seocndary endpoints! No it wasnt a miss. 2. Lyme disease vaccine is actually one of the few pushed by Kennedy! 3. 470000 infections a year in US alone. If burden is reduced by 280000 (70% reduction) then the benefit is massive. 3. The talk is about a potential early meetings because of the interest on the two regulatory sides. 4. Pfizer would make a move and acquire valneva. a 100%-150% premium and its theirs!.

1 · Reply

prismmarketview Mar. 23 at 3:30 PM

$PFE $VALN pushing forward on Lyme disease vaccine despite missing Phase 3 primary endpoint. The case: 70%+ efficacy. No safety concerns. Zero approved competition since 2002. 476K U.S. cases/year. FDA submission planned for 2026. Peak sales est. $1B+. The risk: regulators may not look past the trial miss. Under the current FDA climate, this one's a real wildcard. 🎯 Not financial advice. Regulatory outcome pending. https://prismmarketview.com/pfizer-is-pushing-forward-on-a-lyme-disease-vaccine-even-after-missing-its-trial-goal/

0 · Reply

tt01 Mar. 23 at 2:43 PM

$VALN Massive selling??

0 · Reply

SmarterThanYouandYou Mar. 23 at 2:36 PM

$VALN According to google anything >50% is considered effective and 70-90% is preferred *73..28* reported... Given there is no current vaccine for Lyme in US and NO ADVERSE effects reported I am completely confused by reaction. I live in an area with a lot of Lyme disease cases and I do a lot of outdoor activities. I will get this vaccine if made available!

0 · Reply

tt01 Mar. 23 at 2:35 PM

$VALN why going down?

0 · Reply

kylevallans Mar. 23 at 2:11 PM

Losers Today: $HKIT $LNKS $DTCK $VALN $FMFC Download this scanner: https://stockanalysis.com/markets/losers/?ref=saveontrading

2 · Reply

Dr_Jan_Itor Mar. 23 at 1:46 PM

$VALN If 73,2% isn’t enough, what is?

1 · Reply

tt01 Mar. 23 at 1:18 PM

$VALN what happened?

0 · Reply

kylevallans Mar. 23 at 1:16 PM

Market Bullets: Futures rise after U.S.-Iran talks, ICE to be deployed to airports, CBS News lays off 6% of its staff $PARA.X $BRK.B $BRK.A $PFE $VALN View the free newsletter here: https://stockanalysis.com/market-bullets/2026-03-23/?ref=saveontrading

0 · Reply

UnoffensiveName Mar. 23 at 1:15 PM

$VALN 07:34 AM EDT, 03/23/2026 (MT Newswires) -- Pfizer (PFE) and Valneva (VALN) said Monday that their investigational vaccine candidate LB6V against outdoor Lyme disease reduced the rate of confirmed cases by 73.2% compared with placebo in a phase 3 clinical study. The efficacy result came 28 days after the fourth dose in the second season of the study, the companies said. Meanwhile, an efficacy of 74.8% in preventing Lyme disease was observed a day after the fourth dose in the second season of the trial, the companies said. "Fewer than anticipated" infections were accrued over the study period, and Pfizer is planning further regulatory submissions for the vaccine candidate, the companies added. LB6V is being jointly developed by Pfizer and Valneva

0 · Reply

notreload_ai Mar. 23 at 1:12 PM

$PFE and $VALN reported their Lyme disease vaccine demonstrated 73.2% efficacy in the Phase 3 VALOR trial. While it missed the primary statistical target due to fewer cases, strong results support upcoming regulatory submissions. https://notreload.xyz/pfizer-valneva-lyme-vaccine-shows-73-efficacy-in-phase-3/

0 · Reply

BallinBearBull Mar. 23 at 1:00 PM

$VALN regardless of how data is interpreted, shares are being sold off because now there will not be any meaningfulcatalysts for many MONTHS

0 · Reply

etrade Mar. 23 at 12:27 PM

$VALN technically we see 5.3 this week

1 · Reply

buzzkiller Mar. 23 at 12:26 PM

$VALN 73% efficacy and Pfizer is filing with regulators. Your CI takes more victims than Lyme disease did in the trial. Stay poor.

1 · Reply